FGF23 and X-linked hypophosphatemia: Monitoring of FGF23 concentrations is not helpful in the management of patients with XLH as treatment with phosphate and active vitamin D stimulate FGF23 levels and burosumab interferes with the analytic assays leading to unreliable results [48, 49].